Change in the total number of shares and votes in Recipharm AB (publ)

In February 2015, the number of shares in Recipharm AB (publ) (“Recipharm”) has
increased by 2,915,544 shares of series B, corresponding to 2,915,544 votes. The
increase in the number of shares and votes results from conversion of
convertible bonds issue in connection with the acquisition of Corvette
Pharmaceutical Services Group, completed on 1 October 2015. Following the
conversion of convertible bonds as set out above there are no outstanding
convertible bonds in Recipharm.
As of 27 February 2015, the total number of shares in Recipharm amounts to
45,719,418, divided into 12,685,716 shares of series A and 33,033,702 shares of
series B. The total number of votes in Recipharm as of 27 February 2014 amounts
to 159,890,862.

This information is published in accordance with Chapter 4, Section 9 of the
Swedish Financial Instruments Trading Act (SFS 1991:980).

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10

Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
Nasdaq Stockholm. This information was submitted for publication on 27 February
2015, at 08:00 am CET.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com